Paragraph IV Certification

What It Means

A Paragraph IV certification is a declaration in an Abbreviated New Drug Application (ANDA) in which a generic drug manufacturer asserts that one or more patents listed in the FDA's Orange Book for the reference brand-name drug are either invalid, unenforceable, or will not be infringed by the proposed generic product. It is named after paragraph IV of Section 505(j)(2)(A) of the Federal Food, Drug, and Cosmetic Act, as amended by the Hatch-Waxman Act. Filing a Paragraph IV certification is one of the most aggressive and consequential moves a generic manufacturer can make. It is treated as an act of patent infringement by law, giving the brand-name patent holder standing to sue immediately — even though the generic product has not yet been manufactured or sold. If the brand-name company files suit within 45 days of receiving notice, the FDA automatically imposes a 30-month stay on generic approval, keeping the generic off the market while the litigation plays out. This 30-month stay is one of the most powerful patent-extension tools available to brand companies. The first generic applicant to file a Paragraph IV certification on a particular drug receives a reward: 180 days of marketing exclusivity as the only generic on the market. This first-filer exclusivity is enormously valuable, often generating hundreds of millions in revenue, because a single generic competitor typically captures most of the market while pricing remains relatively high compared to the multi-generic equilibrium that follows. Paragraph IV challenges are the primary mechanism through which generic drugs enter the market before brand patents naturally expire, making them a central feature of pharmaceutical patent strategy and patent cliff timing.

Frequently Asked Questions